Overview
Exercise-induced hyperinsulinism (EIHI), also known as exercise-induced hyperinsulinemic hypoglycemia, is a rare genetic disorder characterized by inappropriate and excessive insulin secretion triggered by strenuous physical exercise. This condition is caused by activating mutations in the SLC16A1 gene (also known as MCT1), which encodes monocarboxylate transporter 1. Normally, this transporter is not expressed in pancreatic beta cells, but gain-of-function mutations lead to its ectopic expression, allowing pyruvate and lactate generated during exercise to enter beta cells and stimulate insulin release. This results in episodes of hypoglycemia (dangerously low blood sugar) during or shortly after vigorous anaerobic exercise. The primary body system affected is the endocrine/metabolic system, specifically the insulin-regulating function of the pancreas. Key clinical features include recurrent hypoglycemic episodes provoked by exercise, which can manifest as confusion, dizziness, weakness, seizures, and loss of consciousness. Importantly, patients typically do not experience hypoglycemia during fasting or in the absence of exercise, which distinguishes this condition from other forms of congenital hyperinsulinism. Symptoms often become apparent in childhood when children begin engaging in more vigorous physical activities. Management of exercise-induced hyperinsulinism focuses on preventing hypoglycemic episodes. Patients are advised to avoid intense anaerobic exercise or to consume carbohydrate-rich snacks before and during physical activity. Diazoxide, a medication that suppresses insulin secretion, may be used in some cases, though its effectiveness can vary. Unlike some other forms of congenital hyperinsulinism, surgical intervention (pancreatectomy) is generally not required. With appropriate dietary management and activity modification, most patients can lead relatively normal lives, though careful monitoring remains important.
Also known as:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Childhood
Begins in childhood, roughly ages 1 to 12
FDA & Trial Timeline
3 eventsTexas Christian University — NA
University of Pittsburgh — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Exercise-induced hyperinsulinism.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Exercise-induced hyperinsulinism at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Exercise-induced hyperinsulinism.
Community
No community posts yet. Be the first to share your experience with Exercise-induced hyperinsulinism.
Start the conversation →Latest news about Exercise-induced hyperinsulinism
Disease timeline:
New recruiting trial: Ambient Air and Noise Effect on Cardiovascular Health Risk and Lifestyle Intervention to Attenuate It (METSGREEN)
A new clinical trial is recruiting patients for Exercise-induced hyperinsulinism
New recruiting trial: mTOR as Mediator of Insulin Sensitivity Study
A new clinical trial is recruiting patients for Exercise-induced hyperinsulinism
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Exercise-induced hyperinsulinism
What is Exercise-induced hyperinsulinism?
Exercise-induced hyperinsulinism (EIHI), also known as exercise-induced hyperinsulinemic hypoglycemia, is a rare genetic disorder characterized by inappropriate and excessive insulin secretion triggered by strenuous physical exercise. This condition is caused by activating mutations in the SLC16A1 gene (also known as MCT1), which encodes monocarboxylate transporter 1. Normally, this transporter is not expressed in pancreatic beta cells, but gain-of-function mutations lead to its ectopic expression, allowing pyruvate and lactate generated during exercise to enter beta cells and stimulate insuli
How is Exercise-induced hyperinsulinism inherited?
Exercise-induced hyperinsulinism follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Exercise-induced hyperinsulinism typically begin?
Typical onset of Exercise-induced hyperinsulinism is childhood. Age of onset can vary across affected individuals.
Which specialists treat Exercise-induced hyperinsulinism?
10 specialists and care centers treating Exercise-induced hyperinsulinism are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.